Alla studier
RekryteringFAS2INTERVENTIONELL

AEF0217 in Participants With Down Syndrome

This research study is testing a new medication called AEF0217 for individuals with Down Syndrome, specifically those aged 16 to 32. The main goals are to find out if AEF0217 can improve daily life skills and thinking abilities, as well as to check if it's safe to use. Participants will be randomly assigned to take one of two doses of AEF0217 or a placebo (a dummy pill with no active drug) every day for 24 weeks. Researchers will closely monitor their progress through clinic visits, tests, and phone calls. This study takes place in clinics across Spain, France, and Italy and involves about 188 people.

Överblick

Status
Rekrytering
Fas
FAS2
Sponsor
Aelis Farma
Inskrivningsmål
188
Starta
22 dec 2025
Beräknad slutförande
31 dec 2027

Vad handlar denna studie om?

You might be interested in a research study looking at a new medication called AEF0217 for people with Down Syndrome. This study is designed to explore whether AEF0217 can help improve daily life activities and thinking skills in adults and older teenagers with Down Syndrome. It's a 'Phase 2' study, which means researchers are trying to get a better understanding of the drug's effects and safety in a larger group of people, after earlier smaller studies have suggested it might be helpful.

The main questions this study hopes to answer are: Can AEF0217 improve how people with Down Syndrome manage their daily tasks after taking it for 24 weeks? Does it also help with different types of thinking skills, improve quality of life, and sleep? And importantly, what are the possible side effects or medical problems that people might experience when taking AEF0217? By answering these questions, researchers hope to learn if AEF0217 could be a useful new treatment option in the future.

To ensure fair results, some participants will receive the actual medication, while others will receive a 'placebo'. A placebo looks exactly like the study drug but contains no active medicine. This allows researchers to compare the effects of the active drug against no treatment. No one, not even the doctors or nurses, will know who is receiving which until the end of the study. This is called a 'double-blind' study and helps ensure the results are as accurate as possible.

Viktiga punkter

  • Tests a new medication (AEF0217) for Down Syndrome.
  • Aims to improve daily activities and thinking skills.
  • Involves taking the drug or a dummy pill for 24 weeks.
  • Includes regular clinic visits and phone calls.
  • Deltagande är frivilligt och du kan lämna när som helst.
  • Takes place in clinics across Spain, France, and Italy.

Vem kan vara berättigad?

To join this study, people need to be between 16 and 32 years old and have a confirmed diagnosis of Down Syndrome. They should be able to move around on their own and have good enough sight and hearing to take part in the tests. The study also requires participants to have a certain level of understanding and communication skills, which will be checked by the study team.

It's important that participants have a parent or strong caregiver who can come to all the clinic visits with them. This caregiver will also help make sure the participant takes their study medicine as agreed and provides information about how they are doing. This ensures consistent care and accurate feedback for the research team.

For safety, both male and female participants will need to follow specific guidelines regarding contraception throughout the study. This is common in drug trials to prevent any potential risks to unborn babies. The study team will explain these rules clearly if you are considering joining.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. Are you between 16 and 32 years old?
  2. Do you have a diagnosis of Down Syndrome?
  3. Can you move around on your own?
  4. Do you have a parent or caregiver who can attend all appointments with you?
  5. Are you able to understand and follow instructions for the study?
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

If you decide to take part, you will take either AEF0217 or a dummy pill every day for 24 weeks. Throughout this time, you will visit the clinic 6 times with your caregiver for check-ups, where you'll do tests on a tablet and answer questions. These visits include an initial check, three visits during the treatment period (at weeks 4, 12, and 24), and a final follow-up visit 8 weeks after you stop taking the study medication.

In between clinic visits, you'll receive 5 phone calls at home to check how you're feeling and if everything is going well. During these visits and calls, the study team will monitor your progress, safety, and how well the treatment might be working. This includes looking at your daily activities, thinking skills, quality of life, and sleep. We will also take blood and urine samples to check for any changes.

After completing the 24 weeks of treatment, and if it's approved, you might be invited to continue into an extra 12-month study where everyone gets the active drug. If you don't wish to join this extension, you will have a final follow-up 8 weeks after your treatment ends. The total time you'd be involved in the study, from start to finish, would be about 36 weeks.

Potentiella risker och fördelar

Taking part in any study has potential benefits and risks. While there's no guarantee that AEF0217 will help you, there's a chance it could improve your daily activities or thinking skills. You'll also receive regular medical checks and oversight from a dedicated healthcare team. On the other hand, there's a possibility of experiencing side effects from the medication. The study team will carefully monitor you for any medical problems and will provide support. Remember, taking part is completely voluntary, and you are free to leave the study at any time, for any reason, without it affecting your usual medical care.

Platser (10)

  • CHU de Bordeaux
    Verifierat postnummer
    Bordeaux, Frankrike· Rekryterar inte ännu
  • Genetics department, Hospices Civils de Lyon
    Verifierat postnummer
    Lyon, Frankrike· Rekryterar inte ännu
  • Service Génétique Médicale, CHU de Montpellier
    Verifierat postnummer
    Montpellier, Frankrike· Rekrytering
  • Genetics department, Institut Jérôme Lejeune
    Verifierat postnummer
    Paris, Frankrike· Rekrytering
  • Service de Génétique, Chromosomique et Moléculaire, Chu de Saint Etienne
    Verifierat postnummer
    Saint-Etienne, Frankrike· Rekrytering
  • IRCCS Istituto Delle Scienze Neurologiche, Azienda Unita Sanitaria Locale Di Bologna
    Verifierat postnummer
    Bologna, Italien· Rekrytering
  • Centro di Medicina dell'Invecchiamento, Policlinico Universitario Agostino Gemelli IRCCS
    Verifierat postnummer
    Rom, Italien· Rekrytering
  • UOR of Neurofarmacology and Translational Neurosciences, Associazione Oasi Maria S.S.Onlus
    Verifierat postnummer
    Troina, Italy· Rekrytering
  • Integrative Pharmacology and Systems Neurosciences, Hospital del Mar Research Institute
    Verifierat postnummer
    Barcelona, Spanien· Rekrytering
  • Servicio de Medicina Interna, Hospital Universitario De La Princesa
    Verifierat postnummer
    Madrid, Spanien· Rekryterar inte ännu

Vanliga frågor

What is AEF0217?

AEF0217 is a new medication being tested to see if it can help people with Down Syndrome with their daily activities and thinking skills.

Vad är en 'placebo'?

A placebo is a dummy pill that looks exactly like the study medicine but doesn't contain any active drug. It helps researchers compare the effects of the active medicine against no treatment.

Hur länge kommer jag att vara med i studien?

The study will last about 36 weeks in total. This includes 24 weeks of taking the study medicine and some follow-up appointments afterwards.

Vad händer om jag vill sluta delta?

Du är fri att lämna studien när som helst, av vilken anledning som helst, utan att det påverkar din medicinska vård.

Where does the study take place?

This study is happening in several medical centres across Spain, France, and Italy.

Hur du får reda på mer

Stéphanie Monlezun, Ph. D

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Intresserad av att delta?

Registrera ditt intresse

Dela dina uppgifter och forskarteamet för "AEF0217 in Participants With Down Syndrome…" kommer att kontakta dig om du kan vara berättigad. Prata alltid med din läkare innan du går med på att delta.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.